Low Level Laser Treatment of Tendinopathy: A Systematic Review with Meta-analysis

Steve Tumilty, MPhty,¹ Joanne Munn, Ph.D.,¹ Suzanne McDonough, Ph.D.,² Deirdre A. Hurley, Ph.D.,³ Jeffrey R Basford, Ph.D.,⁴ and G. David Baxter, DPhil¹

Abstract

Objectives: To assess the clinical effectiveness of Low Level Laser Therapy (LLLT) in the treatment of tendinopathy. Secondary objectives were to determine the relevance of irradiation parameters to outcomes, and the validity of current dosage recommendations for the treatment of tendinopathy. Background: LLLT is proposed as a possible treatment for tendon injuries. However, the clinical effectiveness of this modality remains controversial, with limited agreement on the most efficacious dosage and parameter choices. Method: The following databases were searched from inception to 1st August 2008: MEDLINE, PubMed, CINAHL, AMED, EMBASE, All EBM reviews, PEDro (Physiotherapy Evidence Database), SCOPUS. Controlled clinical trials evaluating LLLT as a primary intervention for any tendinopathy were included in the review. Methodological quality was classified as: high (≥ 6 out of 10 on the PEDro scale) or low (<6) to grade the strength of evidence. Accuracy and clinical appropriateness of treatment parameters were assessed using established recommendations and guidelines. Results: Twenty-five controlled clinical trials met the inclusion criteria. There were conflicting findings from multiple trials: 12 showed positive effects and 13 were inconclusive or showed no effect. Dosages used in the 12 positive studies would support the existence of an effective dosage window that closely resembled current recommended guidelines. In two instances where pooling of data was possible, LLLT showed a positive effect size; in studies of lateral epicondylitis that scored ≥ 6 on the PEDro scale, participants' grip strength was 9.59 kg higher than that of the control group; for participants with Achilles tendinopathy, the effect was 13.6 mm less pain on a 100 mm visual analogue scale. Conclusion: LLLT can potentially be effective in treating tendinopathy when recommended dosages are used. The 12 positive studies provide strong evidence that positive outcomes are associated with the use of current dosage recommendations for the treatment of tendinopathy.

Introduction

I N RECENT TIMES, the term "Tendinopathy" has been used as a general clinical descriptor to indicate pain in the region of the tendon without any indication of the underlying cause.¹ However, the prevalence of tendinopathies is apparently increasing. For example, in New Zealand the incidence of Achilles tendon ruptures more than doubled between the years 1998 to 2003, from 4.7/100,000 to 10.3/100,000, a phenomenon that follows international trends.² Patella tendinopathy accounted for 20% of all knee injuries reported over a six month period at a sports injury clinic,³ while tennis elbow affects approximately 1%–2% of the population.⁴ Other common sites of tendinopathy are golfer's elbow at the medial side of the elbow, and the rotator cuff tendons in the shoulder. Perhaps because of the multifactorial nature of the pathogenesis of tendinopathy,^{5,6} there is a plethora of treatment modalities available to reduce symptoms and to attempt to control or enhance the tendon healing response. These modalities, which include various electrotherapy modalities, eccentric exercise, a variety of injection techniques, and crossfiber massage, provide mixed or uneven benefit across patient populations.^{7–9}

Low level laser therapy (LLLT) or the use of laser sources at powers too low to cause measurable temperature increases, has been used to treat soft tissue injuries and inflammation since the 1960s, and studies from as early as the 1980s reported benefits in a variety of tendon and sports injuries.^{10,11} More recently, the term LLLT has been used to describe not only the use of low power laser sources, but also

¹Centre for Physiotherapy Research, School of Physiotherapy, University of Otago, Dunedin, New Zealand.

²University of Ulster, Newtownabbey, Co Antrim, Northern Ireland.

³University College Dublin, Belfield, Dublin, Republic of Ireland.

⁴Mayo Clinic, Rochester, Minnesota.

monochromatic superluminous diodes. Both types of system have been used in the treatment of various musculoskeletal conditions, including tendon injuries, each apparently with success. Such applications are supported by experimental evidence of the biological effects of LLLT, including increased ATP production, enhanced cell function, and increased protein synthesis.¹² LLLT has also been shown to have positive effects on the reduction of inflammation,¹³ increase of collagen synthesis,¹⁴ and angiogenesis.¹⁵

While LLLT is promoted as a safe and effective form of treatment for a variety of conditions, in today's healthcare climate there is a necessity to practice evidence-based medicine, and a need to provide high level evidence to support the use of any treatment modality. Whether previous research into the effectiveness of LLLT has accomplished this is debatable due to the varying quality of the available research.

With this in mind, a systematic review with a metaanalysis of the data was undertaken to answer the question: "Is Low Level Laser Therapy effective in the treatment of tendinopathy?" Three main objectives were set:

- a) to determine the clinical effectiveness of LLLT in the treatment of tendinopathy when compared to placebo, no treatment, or other types of intervention;
- b) to determine the relevance of irradiation parameters to reported positive outcomes;
- c) to determine the validity of current dosage recommendations for the treatment of tendinopathy.

Materials and Methods

Search strategy

The MEDLINE (1966-1st Aug 2008), PubMed (1950-1st Aug 2008), CINAHL (1982-1st Aug 2008), AMED (1985-1st Aug 2008), EMBASE (1988-1st Aug 2008), All EBM (Evidence Based Medicine) reviews, PEDro (Physiotherapy Evidence Database), and SCOPUS (1960-1st Aug 2008) databases were searched (Table 1).

Selection criteria for this review: types of studies

Fully reported randomized controlled trials (RCTs) and controlled clinical trials (CCTs) from peer reviewed journals were included. No language restrictions were made.

Selection criteria for this review: types of participants

Human participants who had been diagnosed with tendinopathy and exhibited pain and/or functional disability were included. There was no distinction made with regards to age, gender, level of activity or chronicity of the injury.

Selection criteria for this review: types of interventions

One group in the controlled trial must have involved participants treated with active LLLT. Comparisons were made with at least one of the following: placebo, no treatment, or other treatments such as medication, exercise therapy or other electrotherapy modalities. Interventions based upon combinations of LLLT and other modalities were not considered for the review.

Selection criteria for this review: types of outcome measure

Trials which assessed pain or function for at least one of the outcome measures were considered for inclusion.

Retrieval of relevant articles

Two independent reviewers (ST and JM) applied the selection criteria to the titles and abstracts of articles retrieved by the electronic search. All trials classified as relevant by either of the reviewers were retrieved. When there was insufficient information in the title or abstract to determine eligibility, the full text of the article was retrieved. Where there was disagreement between the two reviewers about a trial's eligibility, the retrieved trial was re-examined against the selection criteria, and disagreement resolved by consen-

Phase 1	Phase 2	Phase 3
1. Tend\$.mp.	18. randomized control trial.pt.	27. clinical trial.pt.
2. Tendinopathy	19. controlled clinical trial.pt.	28. exp Clinical Trials/
3. Soft Tissue Injuries/	20. Randomized Controlled Trials/	29. (clinic adj25 trial\$).tw.
4. Tendon Injuries/	21. Random Allocation/	30. ((singl\$ or doubl\$ or trebl\$ or tripl\$) adj (mask\$ or blind\$)).tw.
5. Achill\$.mp.	22. Double-Blind Method/	31. Placebos/
6. Patell\$.mp.	23. Single-Blind Method/	32. placebo\$.tw.
7. Epicondyl\$.mp.	24. or/18–23	33. random\$.tw
8. Tennis Elbow.mp.	25. Animal/not Human/	34. Research Design/
9. Golfers Elbow.mp	26. 24 not 25	35. or/27–34
10. Rotator Cuff.mp.		36. 35 not 25
11. (jumper\$ adj knee).mp.		37. 35 not 26
12. or/1–11		38. and/17,26
13. laser.mp.		39. and/17,37
14. low level laser therapy.mp.		
15. LLLT.mp. 16. or/13–15 17. and/12,16		40. or/38–39

TABLE 1. SEARCH STRATEGY

sus. For studies published in languages other than English, a translation was obtained.

Quality assessment

Three independent reviewers (ST, SM & DH) assessed the included articles for methodological quality against the PEDro scale.¹⁶

Data extraction

Three reviewers (ST, JB & GDB) independently extracted and recorded the necessary details about diagnosis, interventions, and LLLT parameters, in line with recommendations by the World Association for Laser Therapy (WALT)¹⁷ to determine the parameters and method of delivery of laser therapy.

Analysis

The recommendations of Van Tulder et al.¹⁸ regarding levels of evidence were used to interpret the results:

Strong evidence: consistent findings among multiple higher quality RCTs;

Moderate evidence: consistent findings among multiple lower quality RCTs and/or one higher quality RCT;

Limited evidence: one lower quality RCT;

Conflicting evidence: inconsistent findings among multiple RCTs;

No evidence: no RCTs.

Pooling of data

Where available, data were pooled as follows:

Pain: used a visual analogue scale (VAS) for both final scores and change in scores;

Site of injury: i.e., for lateral epicondylitis, Achilles tendinopathies, rotator cuff injuries; Grip strength.

To investigate the relevance of parameters to reported benefits, studies were also grouped into those reporting positive effects and those reporting inconclusive or no effects.

Statistical analysis

Where pooling of data was justified, results were expressed as relative risks (RR) and 95% confidence intervals (CI) for dichotomous outcomes, and weighted mean difference (WMD) and 95% confidence intervals calculated for continuous outcomes. Testing for heterogeneity was done using the chi-square test. Test results for heterogeneity determined whether a random or fixed effects model was used.

Disagreements between reviewers were settled by consensus. Where insufficient data was provided in the published article, every attempt was made to contact the authors to obtain the relevant information.

Results

The Quality of Reporting of Meta-Analysis (QUOROM) statement flow diagram¹⁹ (Fig. 1) displays the results of the search conducted on 1st August 2008. As shown, 663 investigations were identified as being potentially relevant according to the initial search criteria. Of these, 638 reports were excluded at various stages of the process for a variety of

reasons, including: they were review articles; they involved surgery or did not involve LLLT; they did not address tendinopathy; they included inappropriate LLLT intervention/ application techniques; they were not an RCT/CCT; they were not full reports; or they did not appear in peerreviewed journals. Twenty-five articles were included in the review (Table 2 and Table 3).

Assessing the level of evidence for the effectiveness of LLLT in the treatment of tendinopathy based upon van Tulder's recommendations (see Table 3),¹⁸ the evidence for the effectiveness of LLLT in the treatment of tendinopathy is inconclusive, as there are conflicting findings among multiple RCTs: twelve studies reported a positive effect (Table 4), and thirteen studies reported no effect or inconclusive results (Table 5).

Twelve studies provided sufficient detailed data to input into RevMan 4.2 (Cochrane Collaboration, Copenhagen, Denmark²⁰) to calculate effect sizes for the outcome measures of final pain scores and pain change scores measured on a VAS (Fig. 2), or, for lateral epicondylitis, grip strength (Fig. 3). These twelve studies are indicated by** in Tables 4 and 5.

Attempts to pool data from multiple studies were not valid as the test for heterogeneity was significant (p < 0.05) for most of the analyses. However, to show the effect of individual comparisons, for studies that compared LLLT against more than one other group, data comparing LLLT against all other modalities were included in the analysis (Fig. 2). For example, in a poorly powered study by Hernandez-Herrero et al.²⁴ in which LLLT was compared against four other modalities of treatment for elbow tendinosis, it can be seen that there was very little difference between LLLT and the other forms of treatment. Of the studies that showed a positive result of LLLT for pain, the effects ranged from 2.1-28 mm on a 100 mm VAS (Fig. 2).

It was valid to pool data in two instances: the first for participants' grip strength in studies of lateral epicondylitis that scored ≥ 6 on the PEDro scale (Fig. 3); in the second instance, for pain scores in Achilles tendinopathy (Fig. 4). Effect sizes corresponded to grip strength values of 9.59 kg greater than the control group for participants with lateral epicondylitis, and 13.6 mm less pain on a 100 mm VAS for participants with Achilles tendinopathy.

Results for pain scores categorized by site of injury are displayed in Figure 4. Three studies reported pain change scores for rotator cuff injuries treated with LLLT.^{35–37} Of these, two compared LLLT to placebo,^{35,37} while Saunders et al.³⁶ included three groups: LLLT, placebo, and ultrasound. Assessment by change in pain between initial and final assessments all showed a positive effect in favor of LLLT.

Of the two studies which investigated Achilles tendinopathy,^{39,40} both showed positive effects in terms of pain scores at the final assessment, with a pooled effect size of 13.64 mm in favor of the LLLT groups.

Final pain scores were analyzed for participants with lateral epicondylitis. Figure 4 shows multiple comparisons from single studies, so that determination of a pooled effect size was not possible. Of the five studies, two showed no effect of LLLT on participants' pain,^{21,24} and three resulted in a positive effect on pain.^{27,29,31}

Table 4 displays those studies reporting positive effects of LLLT, as concluded by the authors of the individual studies,




FIG. 1. Search Strategy Flow Diagram Search strategy used to screen articles against the inclusion/exclusion criteria to generate the final list of articles for analysis.

along with the parameters used. Five studies (marked**) provided data that were used in the RevMan analysis. Table 5 displays studies reporting inconclusive results or no effect from LLLT. It should be noted that even though three studies^{29,37,40} reported no significant differences between groups, in the RevMan analysis the effect sizes of these studies favored the group treated with laser.

Using the parameters reported in Table 4, a range of effective dosages can be calculated for each injury site. These can then be compared to the current recommendations from WALT¹⁷ and from Bjordal et al.⁴⁵ (Table 6). These guidelines state that power densities below $100 \,\text{mW/cm}^2$ should be used for superficial tendons with an energy dose range of 1–8 J. For the deeper tendons of the rotator cuff, power

densities are allowed to go as high as 600 mW/cm^2 , with an energy dose range of 3–9 J.

Epicondylitis

Of thirteen studies investigating the effectiveness of LLLT for epicondylitis, six showed positive results.^{22,25,27,28,31,32} Ten out of the thirteen scored six points or more on the PEDro scale and would be considered of high quality. The positive studies used a wavelength of 904 nm and power densities that lay between 2–100 mW/cm² as recommended by the WALT/Bjordal et al. guidelines.¹³ However, one study³² used a dosage slightly higher then the recommended value (3.5 J/cm² instead of 3 J/cm²) while another²⁸ used a

A SYSTEMATIC REVIEW OF LLLT FOR TENDINOPATHY

Author	Year	Diagnosis	п	Interventions	Outcomes reported
Basford ²¹	2000	Lateral epicondylitis	47	Laser vs. placebo	VAS for pain, VAS for tenderness to palpation, VAS for patient's perception of change (benefit). Grip strength;
Haker ²² Haker ²³	May 91 Nov 91	Lateral epicondylalgia Lateral epicondylalgia	49 58	Laser vs. placebo Laser vs. placebo	pinch strength Grip strength Patient satisfaction (5 point scale) Grip strength
Hernandez-Herrero ²⁴	2006	Elbow tendinosis	46	Laser vs. other electrotherapy modalities	VAS for pain VAS for function DASH questionnaire
Konstantinovic ²⁵	1997	Radiohumeral epicondylitis	32	Laser vs. corticosteroid injection vs. combination of both	McGill pain questionnaire
Krasheninnikoff ²⁶	1994	Lateral epicondylitis	36	Laser vs. placebo	Pain Dynamic muscle test
Lam ²⁷	2007	Lateral epicondylitis	39	Laser vs. placebo	Number of tender points Mechanical pain threshold Grip strength VAS for pain DASH questionnaire
Melagati ²⁸	1994	Humeral epicondylitis	32	Laser vs. cryotherapy & Iontophoresis	VAS for pain Telethermography
Oken ²⁹	2008	Lateral epicondylitis	58	Laser vs. ultrasound V brace	VAS for pain Grip strength Global assessment of improvement
Papadopoulos ³⁰	1996	Tennis elbow	29	Laser vs. placebo	VAS for pain Strength & endurance scor
Stergioulas ³¹	2007	Lateral epicondylitis	50	Laser vs. placebo	VAS for pain Grip strength ROM Wrist extension strength
Vasseljen ³²	1992	Tennis elbow	30	Laser vs. placebo	Strength measures Goniometric measure of wrist flex VAS for pain Verbal rating scale
Vasseljen ³³	May 92	Tennis elbow	30	Laser vs. deep friction massage & pulsed ultrasound	Strength measures Goniometric measure of wrist flex VAS for pain Verbal rating scale
England ³⁴	1989	Shoulder tendinitis	30	Laser vs. placebo vs. drug treatment	Goniometry of flex, ext, abd VAS of pain, stiffness, function
Saunders ³⁵	1995	Supraspinatus tendinitis	24	Laser vs. placebo	Pain Isometric strength
Saunders ³⁶	2003	Supraspinatus tendinitis	36	Laser vs. ultrasound vs. placebo	Pain Isometric strength
Vecchio ³⁷	1993	Rotator cuff tendinitis	35	Laser vs. placebo	ROM score Painful arc score Resisted movement score VAS for pain VAS for function
Bjordal ¹³	2006	Achilles tendinitis	14	Laser vs. placebo	Inflammatory markers (PGE ₂) Pressure pain threshold

TABLE 2. CHARACTERISTICS OF THE INCLUDED STUDIES

TABLE 2. (CONTINUED)

Author	Year	Diagnosis	п	Interventions	Outcomes reported
Darre ³⁸	1994	Achilles tendinitis	89	Laser vs. placebo	VAS for pain Morning stiffness Swelling Tenderness Crepitation Number of treatments
Stergioulas ³⁹	2008	Achilles tendinopathy	52	Laser vs. placebo	VAS for pain Crepitation Morning stiffness Tenderness during palpation Active dorsiflexion
Tumilty ⁴⁰	2008	Achilles tendinopathy	20	Laser vs. placebo	VISA-A questionnaire VAS for pain Concentric strength Eccentric strength
Costantino ⁴¹	2005	Achilles tendinitis Patella tendinitis epicondylitis	45	Cryoultrasound vs. laser vs. T.e.c.a.r. therapy	VAS for pain Patient satisfaction
Muller ⁴²	1993	Various tendinopathies	48	Laser vs. placebo	VAS for pain
Siebert ⁴³	1987	Med. & lat. epicondylitis, other tendinopathies	64	Laser vs. placebo	4 point verbal rating scale for resting pain, movement pain and pressure pain
Sharma ⁴⁴	2002	De Quervains tenosynovitis	30	Laser vs. placebo	VAS for pain Grip strength

					PE	Dro crite	ria*					
Author	1	2	3	4	5	6	7	8	9	10	11	Score
Basford ²¹	(√)	\checkmark	×	\checkmark	\checkmark	√	×	\checkmark	×	\checkmark	\checkmark	7
Haker ²²	(✓)	\checkmark	×	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	×	\checkmark	×	7
Haker ²³	(x)	\checkmark	×	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	×	\checkmark	×	7
Hernandez-Herrero ²⁴	(́√)	\checkmark	\checkmark	\checkmark	×	×	\checkmark	×	×	×	\checkmark	5
Konstantinovic ²⁵	(✓)	\checkmark	×	×	×	×	×	×	×	×	×	1
Krasheninnikoff ²⁶	(✓)	\checkmark	×	\checkmark	\checkmark	\checkmark	×	×	×	\checkmark	\checkmark	6
Lam ²⁷	(✓)	\checkmark	×	\checkmark	\checkmark	×	×	\checkmark	×	\checkmark	\checkmark	7
Melegati ²⁸	(✓)	×	×	\checkmark	×	×	\checkmark	\checkmark	×	\checkmark	×	4
Oken ²⁹	(✓)	\checkmark	×	\checkmark	×	×	\checkmark	\checkmark	×	\checkmark	\checkmark	6
Papadopoulos ³⁰	(✓)	\checkmark	×	×	\checkmark	\checkmark	×	\checkmark	\checkmark	\checkmark	×	6
Stergioulas ³¹	Ì√)	\checkmark	×	\checkmark	\checkmark	×	\checkmark	×	×	\checkmark	\checkmark	6
Vasselien ³²	(✓)	\checkmark	×	\checkmark	\checkmark	\checkmark	×	\checkmark	\checkmark	\checkmark	\checkmark	8
Vasselien ³³	Ì√)	\checkmark	×	\checkmark	×	×	×	\checkmark	\checkmark	\checkmark	\checkmark	6
England ³⁴	(✓)	\checkmark	×	×	\checkmark	×	\checkmark	\checkmark	×	\checkmark	\checkmark	6
Saunders ³⁵	(✓)	\checkmark	×	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	9
Saunders ³⁶	(✓)	\checkmark	×	\checkmark	×	×	\checkmark	\checkmark	\checkmark	\checkmark	×	6
Vecchio ³⁷	(✓)	\checkmark	×	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	9
Biordal ¹³	(✓)	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	10
Darre ³⁸	(✓)	\checkmark	×	×	\checkmark	\checkmark	×	\checkmark	×	\checkmark	×	5
Stergioulas ³⁹	Ì√)	\checkmark	×	\checkmark	\checkmark	×	\checkmark	×	\checkmark	\checkmark	\checkmark	7
Tumiltv ⁴⁰	(✓)	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	10
Costantino ⁴¹	(x)	×	×	\checkmark	×	×	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	6
Muller ⁴²	(x)	\checkmark	\checkmark	×	\checkmark	\checkmark	×	\checkmark	\checkmark	×	×	6
Siebert ⁴³	(✓)	\checkmark	×	×	\checkmark	×	\checkmark	×	×	×	\checkmark	4
Sharma ⁴⁴	(✓)	×	×	×	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	×	\checkmark	6
<u>*PEDro criteria:</u> 1 - Eligibility criteria? 2 - Random allocation? 3 - Concealed allocation?			5 - Bl 6 - Bl	seline co ind subje ind thera ind asses	cts? pists?	ity?			9 - Int 10 - Bet	equate fo ention-to- ween-gro int estima	treat analy up compa	risons?

 \checkmark = Criterion met; \times = Criterion not met; () = Eligibility criteria item does not contribute to total score.

A SYSTEMATIC REVIEW OF LLLT FOR TENDINOPATHY

Study	Diagnosis	Power density mW/cm ²	Dose J/cm^2	Wavelength nm	PEDro
Haker (May 91) $^{22}_{-}$	Lateral epicondylalgia	60	1.8	904	7
Konstantinovic ²⁵	Radiohumeral epicondylitis	*	*	904	1
Lam ^{27**}	Lateral epicondylitis	218	2.4	904	7
Melagati ²⁸	Humeral epicondylitis	*	150	1064	4
Stergioulas (2007) ^{31**}	Lateral epicondylitis	80	2.4	904	6
Vasseljen (92) ³²	Tennis elbow	*	3.5	904	8
England ³⁴	Shoulder tendinitis	*	*	904	6
Saunders $(95)^{35^{**}}$	Supraspinatus tendinitis	320	19.2	820	9
Saunders (2003) ^{36^m}	Supraspinatus tendinitis	320	19.2	820	6
Biordal ¹³	Achilles tendinitis	20	3.6	904	10
Stergioulas (2008) ^{39**}	Achilles tendinopathy	60	1.8	820	7
Stergioulas (2008) ^{39**} Sharma ⁴⁴	De Quervains tenosynovitis	32	4	830	6

TABLE 4. STUDIES REPORTING POSITIVE EFFECT OF LOW LEVEL LASER THERAPY

*Parameters not provided or insufficient information given to calculate missing parameter.

**These studies are included in the RevMan analysis.

wavelength (1064 nm) and energy density (150 J/cm²) that do not appear in any of the guidelines. Those studies demonstrating no effect^{21,23,24,26,29,30,33} all used power densities and dosage parameters outside of the guidelines, regardless of wavelength employed.

Rotator cuff

Four high quality studies examined the effects of LLLT on tendinopathy around the shoulder region,^{34–37} with three studies^{35–37} using parameters that lay within the guidelines (30–600 mW/cm² & 4.2-42 J/cm²). However, these three provided conflicting results (two positive^{35,36} and one negative³⁷). The study by England et al.³⁴ failed to provide enough detail on irradiation parameters.

Achilles tendinopathy

Four studies investigated LLLT for Achilles tendinopathy.^{13,38–40} Two proved beneficial,^{13,39} and two were inconclusive.^{38,40} The two positive studies used parameters that lay within recommended guidelines,^{13,39} but the others did not.^{38,40} One of the negative studies was deemed of low methodology (less than 6 on the PEDro scale).³⁸

De Quervain's tenosynovitis

One high quality study⁴⁴ used LLLT to treat tendinopathy at the wrist (Table 6); however, there are no recommended guidelines published for that condition. The parameters used are provided in the table.

Discussion

This systematic review and meta-analysis was designed to assess the evidence for the clinical effectiveness of LLLT for the treatment of tendinopathy, the currently accepted terminology used clinically to encompass tendonitis, tendinosis, and insertional tendinopathy. Its secondary objectives were to determine the relationship between irradiation parameters and outcomes and to compare them with the dosage recommendations provided by WALT¹⁷ and from Bjordal et al.⁴⁵ The findings provided conflicting evidence regarding the effectiveness of LLLT for the treatment of tendinopathies.

 Table 5. Studies Reporting Inconclusive Results or no Effect of Low Level Laser Therapy (no Statistically Significant Effect)

Study	Diagnosis	Power density mW/cm ²	Dose J/cm ²	Wavelength nm	PEDro
Basford ^{21**}	Lateral epicondylitis	204	12.24	1060	7
Haker (Nov 91) ²³	Lateral epicondylalgia	*	*	904 and 632.8	7
Hernandez-Herrero ^{24**}	Elbow tendinosis	*	*	*	5
Krasheninnikoff ²⁶	Lateral epicondylitis	114	13.68	830	6
Oken ^{29**}	Lateral epicondylitis	*	*	632.8	6
Papadopoulos ^{30**}	Tennis elbow	400	24	820	6
Vasseljen (May 92) ³³	Tennis elbow	*	3.5	904	6
Vecchio ^{37**}	Rotator cuff tendinitis	422	14	830	9
Darre ³⁸	Achilles tendinitis	150	20.1	830	5
Tumiltv ^{40**}	Achilles tendinopathy	2375	82.4	810	10
Costantino ^{41**}	Various tendinopathies	*	*	*	6
Muller ⁴²	Various tendinopathies	*	*	904	6
Siebert ⁴³	Medial & lateral epicondylitis, other tendinopathies	7500	*	904	4

*Parameters not provided or insufficient information given to calculate missing parameter.

**These studies are included in the RevMan analysis.

Review:	LLLT in the Treatment of Tendinopathy
Comparison:	01 Laser V control

		1		Control		MAD (made a)	Mainhe		
Study or sub-category	N	Laser Mean (SD)	Ν	Control Mean (SE	n	WMD (random) 95% CI	Weight %	VV	MD (random) 95% CI
or sub-category	ia.	mean (OD)		Micun (or	.,		70		3378 01
Basford	23	34.30(28.00)			5.10(21.00)		8.14	9.20	[-5.00, 23.40
Costantino V Cry/us	15	24.70(6.40)			3.30(8.20)	*	9.93	11.40	[6.14, 16.66]
Costantino V TECAR	15	24.70(6.40)			9.30(4.60)	*	10.08	5.40	[1.41, 9.39]
Hernandez V Cryo	14	32.10(34.78)			2.00(18.82)	-+	6.08		[-22.84, 23.0
Hernandez V Electro	14	32.10(34.78)			1.00(28.20)		2.99		[-42.02, 44.2
Hernandez V Sono	14	32.10(34.78)			2.50(32.00)	-+	5.85	-0.40	[-24.44, 23.6
Hernandez V US	14	32.10(34.78)			3.00(26.50)		5.30	-0.90	[-27.68, 25.8
Lam	21	14.80(13.60)		18 4	2.80(21.10)		8.80	-28.00	[-39.35, -16.
Stergioulas 2007	25	6.21(7.70)		25 1	9.67(9.28)	*	10.00	-13.46	[-18.19, -8.7
Oken V Brace	20	43.00(12.00)		20 6	7.00(9.00)	- 82-	9.74	-24.00	[-30.57, -17.
Oken V US	20	43.00(12.00)		18 5	7.00(22.00)		8.78		[-25.44, -2.5
Stergioulas 2008	20	33.00(29.80)		20 5	3.00(19.50)		7.80	-20.00	[-35.61, -4.3
Tumilty	10	16.90(21.92)		10 1	9.00(25.88)		6.51	-2.10	[-23.12, 18.9
	225			197					
Total (95% CI)									
Test for heterogeneity: C Test for overall effect: Z =			1), I ² =	91.0%					
est for overall effect. 2 -	- 1.40 (F -	- 0. 14)							
					-100 -	50 0 50	100		
					Favour	s Laser Favours co	ntrol		
					Favour	s Laser Favours co	ntrol		
					Favour	s Laser Favours co	ntrol		
		t of Tendinopathy			Favour	s Laser Favours co	ntrol		
Comparison: 01 Laser V	control				Favour	s Laser Favours co	ntrol		
Comparison: 01 Laser V Dutcome: 02 Pain Ch	control				Favour	s Laser Favours co	ntrol		
Comparison: 01 Laser V Outcome: 02 Pain Ch Study	control ange score	es		Control		WMD (random)	Weight	w	MD (random)
Comparison: 01 Laser V Dutcome: 02 Pain Ch Study	control	25	N	Control Mean (SE				W	MD (random) 95% Cl
Comparison: 01 Laser V Dutcome: 02 Pain Ch Study or sub-category	control ange score N	es Laser Mean (SD)	N	Mean (SD)	WMD (random) 95% CI	Weight %	100 000	95% CI
Comparison: 01 Laser V Dutcome: 02 Pain Ch Study or sub-category Vecchio	control ange score N 19	Laser Mean (SD) 36.00(9.00)	N	Mean (SD)) 8.00(12.00)	WMD (random) 95% CI	Weight %	18.00	95% CI [10.86, 25.14
Comparison: 01 Laser V Dutcome: 02 Pain Ch Study or sub-category Vecchio Saunders 1995	N 19 12	Laser Mean (SD) 36.00 (9.00) 18.70 (4.39)	N	Mean (SD 16 1 12 -) 8.00(12.00) 6.30(5.56)	WMD (random) 95% CI	Weight % 12.34 12.70	18.00 25.00	95% CI [10.86, 25.14 [20.99, 29.01
Comparison: 01 Laser V Dutcome: 02 Pain Ch Study rsub-category Vecchio Saunders 1995 Papadopoulos	N 19 12 15	Laser Mean (SD) 36.00 (9.00) 18.70 (4.39) 1.60 (10.40)	N	Mean (SD 16 1 12 - 16 1) 8.00(12.00) 6.30(5.56) 4.80(11.40)	WMD (random) 95% CI	Weight % 12.34 12.70 12.26	18.00 25.00 -13.20	95% Cl [10.86, 25.14 [20.99, 29.01 [-20.87, -5.5
Comparison: 01 Laser V Dutcome: 02 Pain Ch Study or sub-category Vecchio Saunders 1995 Papadopoulos Saunders 2003 V Pl	N 19 12 15 12	Laser Mean (SD) 36.00(9.00) 18.70(4.39) 1.60(10.40) 29.80(5.82)	N	Mean (SD 16 1 12 - 16 1 12 -) 8.00(12.00) 6.30(5.56) 4.80(11.40) 1.10(3.37)	WMD (random) 95% CI	Weight % 12.34 12.70 12.26 12.71	18.00 25.00 -13.20 30.90	95% Cl [10.86, 25.14 [20.99, 29.01 [-20.87, -5.5 [27.09, 34.71
Comparison: 01 Laser V Dutcome: 02 Pain Ch Study or sub-category Vecchio Saunders 1995 Papadopoulos Saunders 2003 V PI Saunders 2003 V US	N 19 12 15 12 12 12	Laser Mean (SD) 36.00(9.00) 18.70(4.39) 1.60(10.40) 29.80(5.82) 29.80(5.82)	N	Mean (SD 16 1 12 - 16 1 12 - 12 - 12) 8.00(12.00) 6.30(5.56) 4.80(11.40) 1.10(3.37) 2.10(4.64)	WMD (random) 95% CI	Weight % 12.34 12.70 12.26 12.71 12.68	18.00 25.00 -13.20 30.90 27.70	95% Cl [10.86, 25.14 [20.99, 29.01 [-20.87, -5.5 [27.09, 34.71 [23.49, 31.91
Comparison: 01 Laser V Dutcome: 02 Pain Ch Study or sub-category Vecchio Saunders 1995 Papadopoulos Saunders 2003 V PI Saunders 2003 V US Costantino V Cry/us	N 19 12 15 12 12 15 12 15 15	Laser Mean (SD) 36.00(9.00) 18.70(4.39) 1.60(10.40) 29.80(5.82) 29.80(5.82) 63.30(7.05)	N	Mean (SE 16 1 12 16 1 12 12 15 7) 8.00(12.00) 6.30(5.56) 4.80(11.40) 1.10(3.37) 2.10(4.64) 4.00(7.95)	WMD (random) 95% CI	Weight % 12.34 12.70 12.26 12.71 12.68 12.56	18.00 25.00 -13.20 30.90 27.70 -10.70	95% Cl [10.86, 25.14 [20.99, 29.01 [-20.87, -5.5 [27.09, 34.71 [23.49, 31.91 [-16.08, -5.3
Comparison: 01 Laser V Dutcome: 02 Pain Ch Study or sub-category Vecchio Saunders 1995 Papadopoulos Saunders 2003 V PI Saunders 2003 V US Costantino V Cry/us Costantino V TECAR	N 19 12 15 12 12 15 15 15	Laser Mean (SD) 36.00(9.00) 18.70(4.39) 1.60(10.40) 29.80(5.82) 29.80(5.82) 63.30(7.05) 63.30(7.05)	N	Mean (SE 16 1 12 - 16 1 12 - 12 - 12 15 7 15 6) 8.00(12.00) 6.30(5.56) 4.80(11.40) 1.10(3.37) 2.10(4.64) 4.00(7.95) 7.40(6.80)	WMD (random) 95% CI	Weight % 12.34 12.70 12.26 12.71 12.68 12.56 12.61	18.00 25.00 -13.20 30.90 27.70 -10.70 -4.10	95% Cl [10.86, 25.14 [20.99, 29.01 [-20.87, -5.5 [27.09, 34.71 [23.49, 31.91 [-16.08, -5.3 [-9.06, 0.86]
Comparison: 01 Laser V Dutcome: 02 Pain Ch Study or sub-category Vecchio Saunders 1995 Papadopoulos Saunders 2003 V PI Saunders 2003 V US Costantino V Cry/us Costantino V TECAR	N 19 12 15 12 12 15 12 15 15	Laser Mean (SD) 36.00(9.00) 18.70(4.39) 1.60(10.40) 29.80(5.82) 29.80(5.82) 63.30(7.05)	N	Mean (SE 16 1 12 - 16 1 12 - 12 - 12 15 7 15 6) 8.00(12.00) 6.30(5.56) 4.80(11.40) 1.10(3.37) 2.10(4.64) 4.00(7.95)	WMD (random) 95% CI	Weight % 12.34 12.70 12.26 12.71 12.68 12.56	18.00 25.00 -13.20 30.90 27.70 -10.70 -4.10	95% Cl [10.86, 25.14 [20.99, 29.01 [-20.87, -5.5 [27.09, 34.71 [23.49, 31.91 [-16.08, -5.3
Comparison: 01 Laser V Dutcome: 02 Pain Ch Study or sub-category Vecchio Saunders 1995 Papadopoulos Saunders 2003 V PI Saunders 2003 V US Costantino V Cry/us	N 19 12 15 12 12 15 15 15	Laser Mean (SD) 36.00(9.00) 18.70(4.39) 1.60(10.40) 29.80(5.82) 29.80(5.82) 63.30(7.05) 63.30(7.05)	N	Mean (SE 16 1 12 - 16 1 12 - 12 - 12 15 7 15 6) 8.00(12.00) 6.30(5.56) 4.80(11.40) 1.10(3.37) 2.10(4.64) 4.00(7.95) 7.40(6.80)	WMD (random) 95% CI	Weight % 12.34 12.70 12.26 12.71 12.68 12.56 12.61	18.00 25.00 -13.20 30.90 27.70 -10.70 -4.10	95% Cl [10.86, 25.14 [20.99, 29.01 [-20.87, -5.5 [27.09, 34.71 [23.49, 31.91 [-16.08, -5.3 [-9.06, 0.86]
Comparison: 01 Laser V Dutcome: 02 Pain Ch Study or sub-category Vecchio Saunders 1995 Papadopoulos Saunders 2003 V PI Saunders 2003 V US Costantino V Cry/us Costantino V TECAR Tumilty Fotal (95% CI)	N 19 12 15 12 12 15 15 10 110	Laser Mean (SD) 36.00(9.00) 18.70(4.39) 1.60(10.40) 29.80(5.82) 29.80(5.82) 63.30(7.05) 63.30(7.05) 30.90(11.60)	S a	Mean (SE 16 1 12 - 16 1 12 - 12 - 15 7 15 6 10 2 108) 8.00(12.00) 6.30(5.56) 4.80(11.40) 1.10(3.37) 2.10(4.64) 4.00(7.95) 7.40(6.80)	WMD (random) 95% CI	Weight % 12.34 12.70 12.26 12.71 12.68 12.56 12.61	18.00 25.00 -13.20 30.90 27.70 -10.70 -4.10	95% Cl [10.86, 25.14 [20.99, 29.01 [-20.87, -5.5 [27.09, 34.71 [23.49, 31.91 [-16.08, -5.3 [-9.06, 0.86]
Comparison: 01 Laser V Dutcome: 02 Pain Ch Study or sub-category Vecchio Saunders 1995 Papadopoulos Saunders 2003 V PI Saunders 2003 V US Costantino V Cry/us Costantino V TECAR Tumilty	N 19 12 15 12 15 15 10 110 hi² = 323.0	Laser Mean (SD) 36.00(9.00) 18.70(4.39) 1.60(10.40) 29.80(5.82) 29.80(5.82) 63.30(7.05) 63.30(7.05) 30.90(11.60) Pg. df = 7 (P < 0.00001	S a	Mean (SE 16 1 12 - 16 1 12 - 12 - 15 7 15 6 10 2 108) 8.00(12.00) 6.30(5.56) 4.80(11.40) 1.10(3.37) 2.10(4.64) 4.00(7.95) 7.40(6.80)	WMD (random) 95% CI	Weight % 12.34 12.70 12.26 12.71 12.68 12.56 12.61	18.00 25.00 -13.20 30.90 27.70 -10.70 -4.10	95% Cl [10.86, 25.14 [20.99, 29.01 [-20.87, -5.5 [27.09, 34.71 [23.49, 31.91 [-16.08, -5.3 [-9.06, 0.86]
Comparison: 01 Laser V Dutcome: 02 Pain Ch Study or sub-category Vecchio Saunders 1995 Papadopoulos Saunders 2003 V PI Saunders 2003 V US Costantino V Cry/us Costantino V TECAR Turnilty Fotal (95% CI) Fest for heterogeneity: C	N 19 12 15 12 15 15 10 110 hi² = 323.0	Laser Mean (SD) 36.00(9.00) 18.70(4.39) 1.60(10.40) 29.80(5.82) 29.80(5.82) 63.30(7.05) 63.30(7.05) 30.90(11.60) Pg. df = 7 (P < 0.00001	S a	Mean (SE 16 1 12 - 16 1 12 - 12 - 15 7 15 6 10 2 108) 8.00(12.00) 6.30(5.56) 1.10(3.37) 2.10(4.64) 4.00(7.95) 7.40(6.80) 0.00(7.30)	WMD (random) 95% CI	Weight % 12.34 12.70 12.26 12.71 12.68 12.56 12.61	18.00 25.00 -13.20 30.90 27.70 -10.70 -4.10	95% Cl [10.86, 25.14 [20.99, 29.01 [-20.87, -5.5 [27.09, 34.71 [23.49, 31.91 [-16.08, -5.3 [-9.06, 0.86]
Comparison: 01 Laser V Dutcome: 02 Pain Ch Study r sub-category Vecchio Saunders 1995 Papadopoulos Saunders 2003 V PI Saunders 2003 V US Costantino V Cry/us Costantino V TECAR Tumilty Total (95% CI) Test for heterogeneity: C	N 19 12 15 12 15 15 10 110 hi² = 323.0	Laser Mean (SD) 36.00(9.00) 18.70(4.39) 1.60(10.40) 29.80(5.82) 29.80(5.82) 63.30(7.05) 63.30(7.05) 30.90(11.60) Pg. df = 7 (P < 0.00001	S a	Mean (SE 16 1 12 - 16 1 12 - 12 - 15 7 15 6 10 2 108) 8.00(12.00) 6.30(5.56) 4.80(11.40) 1.10(3.37) 2.10(4.64) 4.00(7.95) 7.40(6.80) 0.00(7.30) -100 -	WMD (random) 95% CI	Weight % 12.34 12.70 12.26 12.71 12.68 12.56 12.61 12.14	18.00 25.00 -13.20 30.90 27.70 -10.70 -4.10	95% Cl [10.86, 25.14 [20.99, 29.01 [-20.87, -5.5 [27.09, 34.71 [23.49, 31.91 [-16.08, -5.3 [-9.06, 0.86]

FIG. 2. Pain analysis with all groups in all studies. When studies included more than two groups or an active control group, the non-laser treatments are shown after the author's name. US, ultrasound; Sono, sonophoresis; Electro, electrophoresis; Cryo, cryotherapy; Cryo/us cryoultrasound; TECAR, capacitive-resistive electric transfer therapy; Brace, tennis elbow brace; Pl, placebo.

However, there was a clear relationship between positive findings and the use of recommended dosages.

Studies reporting benefits (n = 12) were similar in number to those that found no benefit (n = 13). These conflicting results did not appear to be due to methodological quality, however; the studies' methodological scores were generally good (6 or higher on the PEDro scale), with only two positive studies scoring low,^{25,28} compared with three inconclusive studies.^{24,38,43} Perhaps the most important finding of this review is that 12 RCTs (ten high quality and two low quality) demonstrate that LLLT is potentially effective in the treatment of tendinopathy when the recommended irradiation parameters are used.

This finding is perhaps not surprising as a dosagedependent effect should not be unexpected for any effective therapeutic modality. Furthermore, as the body of research grows for a new modality and researchers seek to establish an effective dosage window, conflicting evidence would be expected to accumulate from an ever increasing number of studies; this is seen in the therapeutic ultrasound literature.^{46,47} Under these circumstances, it becomes important to look at the available evidence using methods other than van Tulder's best evidence synthesis, which does not take into account the validity of the intervention used.¹⁸

Twelve studies provided sufficient data to undertake a meta-analysis of effects. Unfortunately, given the variation in interventions used (including different manufacturers, devices, variations in delivery, and calculations of dosages) there was clinical heterogeneity between studies. This can result in misleading conclusions, as differences in treatment parameters and application are important,⁴⁸ and can lead in turn to statistical heterogeneity. Indeed, only two of the meta-analyses (the effect on Achilles tendon pain and the effect on grip strength for lateral epicondylitis) resulted in studies that were homogenous (see Figs. 2–4) and thus allowed calculation of pooled effect results. Other meta-

Study or sub-category	N	Laser Mean (SD)	N	Control Mean (WMD (random) 95% CI	Weight %	W	/MD (random) 95% CI
Basford	23	30.90(30.10)		24	35.40(36.10)		7.38	-4.50	[-23.47, 14.47]
Lam	21	29.57(8.96)		18	21.61(9.70)	*	23.94	7.96	[2.06, 13.86]
Stergioulas 2007	25	40.22(10.45)		25	29.31(8.98)	#	24.90		[5.51, 16.31]
Oken V Brace	20	56.30(11.20)		20	36.20(5.20)	+	24.88		[14.69, 25.51]
Oken V US	20	56.30(11.20)		18	43.60(15.20)		18.90		[4.13, 21.27]
								65.M (8	
Total (95% CI)	109			105					
Test for heterogeneity: Test for overall effect: Z			= 69.8	%					
rescion overall effect. 2	- 0.00 (1	- 0.0001)							
					-100 -50		100		
		nt of Tendinopathy			-100 -50 Favours Cor		1.2.2		
Comparison: 01 Laser V Outcome: 06 Lat Epi	V control	Grip Strength)			Favours Con	ntrol Favours La	iser		
Comparison: 01 Laser \ Outcome: 06 Lat Epi Study	V control icondylitis (Grip Strength) Laser	Ν	Contr	Favours Cor	MMD (random	iser I) Weig	ht	WMD (random)
Comparison: 01 Laser \ Outcome: 06 Lat Epi Study	V control	Grip Strength)	N		Favours Con	ntrol Favours La	iser	pht	WMD (random) 95% CI
Comparison: 01 Laser \ Dutcome: 06 Lat Epi Study or sub-category	V control icondylitis (Grip Strength) Laser	Ν		Favours Cor	WMD (random 95% Cl	iser i) Weig %		95% CI
Comparison: 01 Laser \ Dutcome: 06 Lat Epi Study	V control icondylitis (N	Grip Strength) Laser Mean (SD)	Ν	Mea	Favours Cor rol an (SD)	WMD (random 95% Cl	iser i) Weig % 3.	74	95% CI -4.50 [-23.47, 14
Comparison: 01 Laser V Outcome: 06 Lat Epi Study or sub-category Basford	V control icondylitis (N 23	Grip Strength) Laser Mean (SD) 30.90 (30.10) 29.57 (8.96)	N	Me:	Favours Cor rol an (SD) 35.40 (36.10)	WMD (random 95% Cl	iser i) Weig % 3. 36.	74 08	95% Cl -4.50 [-23.47, 14 7.96 [2.06, 13.8
Comparison: 01 Laser V Dutcome: 06 Lat Epi Study or sub-category Basford Lam	V control icondylitis (N 23 21	Grip Strength) Laser Mean (SD) 30.90(30.10)	N	Mea 24 18	Favours Con rol an (SD) 35.40 (36.10) 21.61 (9.70)	WMD (random 95% Cl	iser i) Weig % 3.	74 08 38	95% CI -4.50 [-23.47, 14
Comparison: 01 Laser V Dutcome: 06 Lat Epi Study or sub-category Basford Lam Stergioulas 2007 Oken V US	V control icondylitis (N 23 21 25 20	Grip Strength) Laser Mean (SD) 30.90 (30.10) 29.57 (8.96) 40.22 (10.45)	N	Mea 24 18 25 18	Favours Con an (SD) 35.40 (36.10) 21.61 (9.70) 29.31 (8.98)	WMD (random 95% Cl	1) Weig % 3. 36. 42. 17.	74 08 38 80	95% Cl -4.50 [-23.47, 14 7.96 [2.06, 13.8] 10.91 [5.51, 16.3] 12.70 [4.13, 21.2]
Comparison: 01 Laser V Dutcome: 06 Lat Epi Study or sub-category Basford Lam Stergioulas 2007	V control icondylitis (N 23 21 25 20 89	Grip Strength) Laser Mean (SD) 30.90(30.10) 29.57(8.96) 40.22(10.45) 56.30(11.20)		Mea 24 18 25	Favours Con an (SD) 35.40 (36.10) 21.61 (9.70) 29.31 (8.98)	WMD (random 95% Cl	1) Weig % 3. 36. 42.	74 08 38 80	95% Cl -4.50 [-23.47, 14 7.96 [2.06, 13.8] 10.91 [5.51, 16.3]

FIG. 3. Lateral epicondylitis grip strength. The upper graph includes both comparisons from Oken et al.²⁹ (2008) and therefore pooling of data is not shown.

analyses resulted in statistical heterogeneity, thus limiting any conclusions from these data.⁴⁹ Given such clinical and statistical heterogeneity from the studies included in this review, we made no attempt to report these combined data.

However, useful information can still be derived from the RevMan analysis by calculating effect sizes from individual studies and making multiple comparisons when studies include more than one other intervention or control group. For this reason, results displayed in Figures 2–4 include effect size calculations for all studies comparing LLLT to all other groups. Sensitivity analyses were attempted using only two groups per study (LLLT *versus* placebo; or LLLT *versus* most commonly used modality from the other groups), and also using only studies scoring ≥ 6 on the PEDro scale. In both instances, outcomes changed very little in magnitude or in the direction of effect (pro or contra LLLT) which also remained constant.

When interpreting these results it should be borne in mind that what is important is whether the effect size is greater than the relevant minimal clinically important difference (MCID) for the outcome measure. For pain scales, both a two point reduction on a ten point scale^{50,51,52} and a 13 mm reduction on a 100 mm scale⁵³ have been reported as MCIDs.⁵⁴ From Figs. 2–4, several instances of effect sizes for LLLT treatments which meet or exceed this MCID can be seen, even though pooling of effect sizes was not always possible: e.g. for participants with rotator cuff injury (Fig. 4).

Some studies used a true placebo group and others used an active control group that received a potentially beneficial therapy. This of course dilutes the effect of the treatment under investigation as the potential difference between a treatment and no-treatment would be greater than comparing the effect of a new treatment against a known beneficial treatment. In fact, the two experimental designs are attempts to answer two different questions; does it work; or is it better than the other? It is beyond the scope of this article to enter the debate over the ethics of placebo,⁵⁵ but the Declaration of Helsinki advocates for the active control orthodoxy.⁵⁶

The present study also aimed to assess the relevance of treatment/irradiation parameters to reported effectiveness. Assessment of results from positive studies provided interesting insights: Table 6 summarizes current results by anatomical site in comparison to guidelines from WALT¹⁷ and Bjordal et al.⁴⁵

Epicondylitis

Four high quality studies provided enough information to allow comparison with guidelines; whereas power densities were within recommendations, dosages (J/cm^2) used in these studies suggest that for epicondylitis the effective dosage window could be widened. Interestingly, of the inconclusive studies, Oken et al.²⁹ actually shows a WMD in favor of laser for both pain and grip strength (Figs. 2–4).

Study or sub-category	N	Laser Mean (SD)	N	Control Mean (SD)	WMD (random) 95% CI	Weight %	WMD (random) 95% Cl
Vecchio	19	36.00(9.00)		16	18.00(12.00)	+	16.02	18.00 [10.86, 25.14]
Saunders 1995	12	18.70(4.39)		12	-6.30(5.56)	*	27.99	25.00 [20.99, 29.01]
Saunders 2003 V PI	12	29.80(5.82)		12	1.10(3.37)		28.97	28.70 [24.89, 32.51]
Saunders 2003 V US	12	29.80(5.82)		12	2.10(4.64)	-	27.02	27.70 [23.49, 31.91]
Total (95% CI) Test for heterogeneity: (Test for overall effect: Z			• 60.3%	52				
					-100	50 0 50	100	
					Favours C			
Review: LLLT in the Comparison: 01 Laser V Outcome: 05 Lat Epic	control	nt of Tendinopathy						
10. 10.	iona ynao p							
Study or sub-category	N	Laser Mean (SD)	N	Control Mean (S	SD)	WMD (random) 95% CI	Weight %	WMD (random) 95% CI
Basford	23	34.30(28.00)		24	25.10(21.00)		12.16	9.20 [-5.00, 23.40]
Hernandez V Cryo	14	32.10(34.78)		7	32.00(18.82)	-	7.46	0.10 [-22.84, 23.04]
Hernandez V Electro	14	32.10(34.78)		2	31.00(28.20)		2.89	1.10 [-42.02, 44.22]
Hernandez V Sono	14	32.10(34.78)		16	32.50(32.00)	-+	7.03	-0.40 [-24.44, 23.64]
Hernandez V US	14	32.10(34.78)		7	33.00(26.50)	-+-	6.08	-0.90 [-27.68, 25.88]
Lam	21	14.80(13.60)		18	42.80(21.10)		14.15	-28.00 [-39.35, -16.65
Stergioulas 2007	25	6.21(7.70)		25	19.67(9.28)	*	18.62	-13.46 [-18.19, -8.73]
Oken V Brace	20	43.00(12.00)		20	67.00(9.00)	*	17.54	-24.00 [-30.57, -17.43
Oken V US	20	43.00(12.00)		18	57.00(22.00)		14.08	-14.00 [-25.44, -2.56]
Total (95% CI)	165			137				
Test for heterogeneity: C	chi ² = 28.4	8, df = 8 (P = 0.0004).	$l^2 = 71.9$	9%				
Test for overall effect: Z								
					-100 -5	50 0 50	100	
					Favours	Laser Favours co	ntrol	
Review: LLLT in the Comparison: 01 Laser V Outcome: 04 Achilles	control	nt of Tendinopathy						
				1997 (J. 1997)				
2007/01/2002	N	Laser Mean (SD)	N	Contro Mean	(SD)	WMD (fixed) 95% CI	Weigh %	t WMD (fixed) 95% Cl
Study or sub-category				20	53.00(19.50)		64.4	6 -20.00 [-35.61, -4.3
	20	33.00(29.80)			그렇게 가 다 안 집에서 많이 많이 많이 다 집안하는 것이		35.5	
or sub-category	20 10	33.00(29.80) 16.90(21.92)		10	19.00(25.88)	-8-	55.5	4 -2.10 (-23.12, 18.5
or sub-category Stergioulas 2008 Tumilty	10				19.00(25.88)			,
or sub-category Stergioulas 2008	10 30	16.90(21.92)	14 29/	10 30	19.00(25.88)	•	100.00	,

FIG. 4. Low Level Laser Therapy Effects on Pain Scores Categorized by Site of Injury. Pooling of data was only valid for Achilles Tendinopathy Pain. When studies included more than two groups or an active control group, the non-laser treatments are shown after the author's name. US, ultrasound; Sono, sonophoresis; Electro, electrophoresis; Cryo, cryotherapy; Cryo/us cryoultrasound; TECAR, capacitive-resistive electric transfer therapy; Brace, tennis elbow brace; Pl, placebo.

However, this study scored only five on the methodology scale and would be classified as low quality. While the wavelength used by Oken et al.²⁹ was not one identified in the guidelines, nevertheless it would be potentially beneficial for the treatment of epicondylitis.

One point to consider when analyzing the effects of any treatment for lateral epicondylalgia is that the pathology of this condition does not always originate from the tendons. The bony insertion may alternatively be the source of the symptoms; this would represent a totally different pathological problem which may respond differently to treatment. As with many trials exploring the treatment of tendon pathologies, the authors of the included trials have not made definitive differential diagnoses. Indeed, it is very difficult to distinguish between tendinosis, tendonitis, and insertional tendinopathy with lateral epicondylitis. Furthermore, elements of all three may well be present.

Rotator cuff

A range of dosages and methods of application was used for treatment of rotator cuff injuries. This may explain the

Injury site	Number of studies	Parameters	World association for laser therapy	Bjordal et al. 2001
Epicondylitis	6	904 nm 1064 nm 60 mW/cm ² 1.8–3.5 J/cm ²	780–860 nm: 4J 904 nm: 1J <100 mW/cm ²	830 nm; 5–100 mW/cm ² 0.7–7 J/cm ² 904 nm; 2–100 mW/cm ² 0.3–3 J/cm ²
Rotator cuff	3	820 nm 904 nm 320 mW/cm ² 19.2 J/cm ²	780–860 nm: 9 J 904 nm: 3 J	830 nm; 30–600 mW/cm ² 4.2–42 J/cm ² 904 nm; 12–600 mW/cm ² 0.4–4 J/cm ²
Achilles	2	820 nm 904 nm 20–60 mW/cm ² 1.8–3.6 J/cm ²	780–860 nm: 8 J 904 nm: 2 J < 100 mW/cm ²	830 nm; 5–100 mW/cm ² 0.7–7 J/cm ² 904 nm; 2–100 mW/cm ² 0.3–3 J/cm ²
Wrist	1	830 nm 32 mW/cm ² 4 J/cm ²	780–860 nm: 8 J 904 nm: 2 J	No guideline

TABLE 6. EFFECTIVE PARAMETERS

conflicting results of two different research groups: two studies by Saunders et al.^{35,36} used standardized treatment points and applied laser three times per week for three weeks; Vecchio et al.³⁷ treated up to five tender points per session and gave two sessions per week for eight weeks. Once again, even though Vecchio et al.³⁷ reported no benefit from the laser treatment, the effect size expressed as WMD (Fig. 4) for pain change scores favored the LLLT group. The mean change in pain for the laser group over the time period studied was twice that of the control group, which would suggest that that analysis of results in the original paper was flawed. On the whole, the effective dose for rotator cuff tendinopathies was found to lie within that recommended by Bjordal et al.⁴⁵

Achilles tendinopathy

Three high quality studies^{13,39,40} and one of low quality³⁸ were included in the review. Bjordal et al.13 measured prostaglandin E₂ (PGE2) over the first two hours following treatment using parameters within his own recommended guidelines.45 Results showed that LLLT was effective in reducing this proxy for inflammation over that time period. Stergioulas et al.³⁹ also used parameters from within the recommended guidelines. Darre et al.³⁸ studied treatment of Achilles tendinopathy in Danish Army recruits, however, the number of treatments given was not standardized, detail on participants was insufficient, and no criteria were given for making the decision to end treatment. The power density and the dose delivered were significantly above what would be considered appropriate by Bjordal⁴⁵ and may explain the lack of reported differences between treatment and control groups. Studies by Stergioulas et al.³⁹ and Tumilty et al.⁴⁰ were very similar in design, in that both looked at LLLT as an adjunct therapy to heavy load eccentric exercise; both used similar wavelengths (810 nm & 820 nm) but the power and energy densities differed. The pilot study⁴⁰ was underpowered as the aim was to gather data to inform a larger RCT in the future; therefore, these results need to be interpreted with this in mind. Once again, the studies reporting beneficial effects support the already published guidelines.

Three other studies reported negative outcomes,^{41,42,43} but the design of these studies, namely the grouping of different tendinopathies together and the lack of adequate reporting of parameters or outcome data, precluded comparison of these findings with other work.

There have been few reviews focusing on the evaluation of the evidence for LLLT in the treatment of tendinopathies. Two Cochrane reviews have looked at interventions for rotator cuff tears and shoulder pain,^{57,58} and made no or weak recommendations as to the effectiveness of LLLT. The rotator cuff study⁵⁷ evaluated physiotherapy interventions but did not adequately define what was included in such an intervention; therefore, no comparison could be made with the current work. The shoulder pain study⁷ came to the conclusion that LLLT was more effective than placebo for adhesive capsulitis but not for rotator cuff tendinopathy. This conclusion was based on the finding of only one study for each condition, apparently due to an inability to determine sufficient detail from two of the other included studies. Another Cochrane review on interventions for treating acute and chronic Achilles tendonitis⁸ concluded that there was insufficient evidence for effectiveness of LLLT, based on one study.

Two reviews looked at lateral epicondylitis;58,59 both reported weak or negative conclusions for the effectiveness of LLLT to treat this condition. In the first review,⁵⁸ the authors acknowledged many methodological weaknesses, but they still recommended that LLLT should not be used as a sole treatment for lateral epicondylitis. However, they did acknowledge that LLLT is a dose-response modality and that the optimum dose has yet to be found. The second article⁵⁹ was a synthesis of other reviews, as well as clinical and randomized controlled trials. Again, and as noted elsewhere,⁶⁰ the review methodology had many shortcomings (inadequate coverage of relevant databases; studies rejected because they were "old"; and insufficient analysis of dosage and knowledge of dosage recommendations). The final conclusion that LLLT was ineffective seemed to be based on the evidence from only two studies, and relied strongly on the results of one study with a good methodology score.

In contrast, a recent review by Bjordal et al.⁶¹ evaluated the evidence from 18 RCTs of LLLT to treat lateral epicondulitis and assessed the validity of treatment procedures and doses. Bjordal et al. concluded that the use of optimal wavelengths and doses resulted in beneficial effects of LLLT, either alone or in conjunction with an exercise program.

Such apparent differences in conclusions are explained in part by the Bjordal's approach in scrutinizing application and dosage information included in RCTs. Independent analysis of reported dosages as miscalculations is important, since such miscalculated dosages are not uncommon in the literature. It is noteworthy that negative reviews of laser therapy for musculoskeletal conditions can be challenged, at least in part, on the basis of inaccurately reported or inappropriate dosages.⁶²

The current review reinforces the validity of this approach, as analysis of results from positive studies can provide evidence of a therapeutic window for effective treatment of tendinopathies.

Limitations of the review

Synthesis of the evidence proved difficult for a number of reasons: although studies scored well in terms of methodological quality, the clinical application of LLLT was either poorly reported or varied between studies. Poor blinding procedures, lack of randomization, and lack of intention to treat analysis may have increased potential biases and weakened the scientific merit of the works reviewed. Lack of use of valid and reliable outcome measures, and inadequate detail in the reporting of these measures, made it difficult to pool data from numerous studies and thus provide any measure of estimated overall effect. We did not perform a hand search of the literature. It might be thought that one would have been beneficial, but the databases targeted and the search strategy used (Table 1) were deemed by the authors to be robust enough to minimize the possibility of missing a significant amount of literature, particularly higher quality trials.

Conclusion

This study found conflicting evidence as to the effectiveness of LLLT in the treatment of tendinopathy. Ten high quality and two low quality RCTs with positive outcomes, compared with ten high quality and three low quality RCTs with negative outcomes, were found. However, there is strong evidence from the 12 positive studies of a correlation between use of recommended dosages and a positive outcome.

The quality of reporting of clinical application techniques and parameters and results needs to be improved in future studies; this would facilitate the pooling of data for a metaanalysis. At present, the heterogeneity of studies often precludes the ability to assess the overall effect of LLLT. Furthermore, for LLLT as for any electrotherapy modality, the application technique and dose must be considered as part of any systematic review.

Finally, the quality of systematic reviews needs to follow some guidelines, such as the QUORUM statement,¹⁹ to ensure a fair and robust evaluation of the evidence.

References

 Maffulli, N., Kahn, K.M., and Puddu, G. (1998). Overuse tendon conditions: Time to change a confusing terminology. Arthroscopy. 14, 840–843.

- Tumilty, S. (2007). Achilles Tendon Rupture: Rising Incidence in New Zealand Follows International Trends. Phys. Ther. Rev. 12, 59–65.
- Kannus, P., Aho, H., Jarvinen, M., and Niittymaki, S. (1987). Computerized recording of visits to an outpatient sports clinic. Am. J. Sports Med. 15, 79–85.
- 4. Gabel, G.T. (1999). Acute and chronic tendinopathies at the elbow. Cur. Opin. Rheumatol. 11, 138–143.
- Riley, G. (2004). The Pathogenesis of Tendinopathy; A Molecular perspective. Rheumatology. 43, 131–142.
- Sharma, P., and Maffulli, N. (2005). Tendon Injury and Tendinopathy: Healing and Repair. J. Bone Joint Surg. Am. 8, 187–202.
- Green, S., Buchbinder, R., and Hetrick, S. (2003). Physiotherapy Interventions for Shoulder Pain. Cochrane Database Syst. Rev. (2):CD004258.
- McLauchlan, G.J., and Handoll, H.H.G. (2001). Interventions for Treating Acute and Chronic Achilles Tendinitis. Cochrane Database Syst. Rev. (2):CD000232.
- Andres, B.M., and Murrell, G.A.C. (2008). Treatment of Tendinopathy: What Works, What Does Not, and What is on the Horizon. Clin. Orthop. Relat. Res. 466(7), 1539–1554.
- Emmanoulidis, O., and Diamantopoulos, C. (1986). CW IR Low-Power Laser Application Significantly Accelerates Chronic Pain Relief Rehabilitation of Professional Athletes. A Double Blind Study. Lasers Surg. Med. 6, 173.
- Roumeliotis, D., Emmanoulidis, O., and Diamantopoulos, C. (1987). C.W. 820 nm 15 mW, 4 J/cm2, laser diode application, in: Sports Injuries. A Double Blind Study. Abstracts, Fifth Annual Congress, 28–30 January 1987. British Medical Laser Association.
- 12. Karu, T. (1989). Photobiology of Low Power Laser Therapy. New York: Harwood.
- Bjordal, J.M., Lopes-Martins, R.A.B., and Iversen, V.V. (2006). A Randomised Placebo Controlled Trial of Low Level Laser Therapy for Activated Achilles Tendonitis with Microdialysis Measurement of Peritendinous Prostaglandin E2 Concentrations. Br. J. Sports Med. 40, 76–80.
- Reddy, G.K., Stehno-Bittel, L., and Enwemeka, C.S. (1998). Laser Photostimulation of Collagen Production in Healing Rabbit Achilles Tendons. Lasers Surg. Med. 22, 281–287.
- Salate, A.C.B., Barbosa, G., Gaspar, P., et al. (2005). Effect of In-Ga-Al-P Diode Laser Irradiation on Angiogenesis in Partial Ruptures of Achilles Tendons in Rats. Photomed. Laser Surg. 23(5), 470–475.
- Centre for Evidence-based research, U.O.S., Sydney. PEDro. Physiotherapy Evidence Database. (2007). Accessed 29th March 2007. http://www.pedro.fhs.usyd.edu.au.
- World Association of Laser Therapy. Dosage Recommendations and Scientific Guidelines. Accessed 5th December 2007. http://www.walt.nu.
- van Tulder, M., Furlan, A., Bombardier, C., Bouter, L., and Editorial Board of the Cochrane Collaboration Back Review Group. (2003). Updated method guidelines for systematic reviews in the Cochrane collaboration back review group. Spine. 28, 1290–1299.
- Moher, D., Cook, D.J., Eastwood, S., Olkin, I., Rennie, D., and Stroup, D.F. (1999). Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOR-OM statement. Quality of Reporting of Meta-analyses. Lancet. 27; 354(9193), 1896–900.
- Review Manager (RevMan) [Computer program]. Version 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.

A SYSTEMATIC REVIEW OF LLLT FOR TENDINOPATHY

- Basford, J.R., Sheffield, C.G., and Cieslak, K.R. (2000). Laser Therapy: A Randomised Control Trial of the Effects of Low Intensity Nd:YAG Laser Irradiation on Lateral Epicondylitis. Arch. Phys. Med. Rehabil. 81, 1504–1510.
- Haker, E.H.K., and Lundeberg, T.C.M. (1991). Is Low Energy Laser Treatment Effective in Lateral Epicondylalgia? J. Pain Symptom Manage. 6, 241–246.
- Haker, E.H.K., and Lundeberg, T.C.M. (1991). Lateral Epicondylalgia: Report of Noneffective Midlaser Treatment. Arch. Phys. Med. Rehabil. 72, 984–988.
- Hernandez Herrero, D., Berjillos Donamayor, A., de la Corte Rodriguez, H., et al. (2006). Estudio Prospectivo Randomizado de Comparacion de Diferentes tecnicas de Electroterapia en Tendinitis de Insercion en Codo. Patologia del Aparato Locomotor. 4, 131–138.
- Konstantinovic, L., Antonic, M., and Brdareski, Z. (1997). Kombinacija Terapije Laserom Niske Snage I Lokalne Infiltracije Kortikosteroida u Tretmanu Radijalnog Epikondilitisa Humerusa. Vojnosanitetski Pregeld. 54(5), 459– 463.
- Krasheninnikoff, M., Ellitsgaard, N., Rogvi-Hansen, B., et al. (1994). No Effect of Low Power Laser in Lateral Epicondylitis. Scand. J. Rheumatol. 23, 260–263.
- Lam, L.K.Y., and Cheing, G.L.Y. (2007). Effects of 904-nm Low Level Laser Therapy in the Management of Lateral Epicondylitis: A Randomized Controlled Trial. Photmed. Laser Surg. 25, 65–71.
- Melegati, G., Miglio, D., Respizzi, S., Giani, E., Volpi, P., and Roi, G.S. (1994). Defocused Nd-YAG Laser Therapy in the Treatment of Humeral Epicondylitis. J. Sports Trauma Rel. Res. 16, 115–122.
- Oken, O., Kahraman, Y., Ayhan, F., Canpolat, S., and Yorgancioglu, Z.R. (2008). The Short-Term Efficacy of Laser, Brace, and Ultrasound Treatment in Lateral Epicondylitis: A Prospective, Randomized, Controlled Trial. J. of Hand Ther. 21, 63–68.
- Papadopoulos, E.S., Smith, R.W., Cawley, M.I.D., and Mani, R. (1996). Low-Level Laser Therapy Does Not Aid the Management of Tennis Elbow. Clin. Rehab. 10, 9–11.
- Stergioulas, A. (2007). Effects of Low Level Laser and Plyometric Exercises in the Treatment of Lateral Epicondylitis. Photomed. Laser Surg. 25, 205–213.
- Vasseljen, O. (1992). Low-Level Laser Versus traditional Physiotherapy in the Treatment of Tennis Elbow. Physiotherapy. 78, 329–334.
- England, S., Farrell, A.J., Coppock, J.S., Struthers, G., and Bacon, P.A. (1989). Low Power Laser Therapy of Shoulder Tendonitis. Scand. J. Rheumatology. 18, 427–431.
- Saunders, L. (1995). The Efficacy of low-Level Laser Therapy in Supraspinatus Tendinitis. Clin. Rehab. 9, 126–134.
- Saunders, L. (2003). Laser Versus Ultrasound in the Treatment of Supraspinatus Tendinosis.: randomised Controlled Trial. Physiotherapy. 89, 365–373.
- Vecchio, P., Cave, M., King, V., Adebajo, A.O., Smith, M., and Hazelman, B.L. (1993). A Double-Blind Study of the Effectiveness of Low Level Laser Treatment of Rotator Cuff tendinitis. Br. J. Rheumatol. 32, 740–742.
- Darre, E.M., Klokker, M., Lund, P., Dejgaard Rasmussen, J., Hansen, K., and Vedtofte, P.E.B. (1994). Laserbehandling af Akillessenetendinit. Ugeskrift for Laeger. 156, 6680–6683.

- 39. Stergioulas, A., Stergioulas, M., Aarskog, R., Lopes-Martins, R.A.B., and Bjordal, J.M. (2008). Effects of Low Level Laser Therapy and Eccentric Exercises in the Treatment of Recreational Athletes with Chronic Achilles Tendinopathy. Am. J. Sports Med. 36, 881–887.
- Tumilty, S., Munn, J., Abbott, J.H., McDonough, S., Hurley, D.A., and Baxter, G.D. (2008). Laser Therapy in the Treatment of Achilles Tendinopathy: A Pilot Study. Photomed. Laser Surg. 26, 25–30.
- Costantino, C., Pogliacomi, F., and Vaienti, E. (2005). Cryoultrasound Therapy and Tendonitis in Athletes: A comparative Evaluation Versus Laser CO₂ and t.e.c.a.r.therapy. Acta Biomedica de L'Ateneo Parmensa. 76, 37–41.
- 42. Muller, F., Gross, M., Grosse, D., Rochet, P., and Sengler, J. (1993). Effet Antalgique du Laser Arsenic-Galium de faible Puissance dans les Tendinites: Protocole en Double Aveugle. Annales de Readaptation et de Medicine Physique. 36, 123– 127.
- 43. Siebert, W., Seichert, N., Siebert, B., and Wirth, C.J. (1987). What is the Efficacy of "Soft" and "Mid" lasers in therapy of Tendinopathies: A double Blind Study. Arch. Orthop. Trauma Surg. 106, 358–363.
- 44. Sharma, R., Thukral, A., Kumar, S., and Bhargarva, S.K. (2002). Effect of Low Level Lasers in de Quervains Tenosynovitis. Physiotherapy. 88, 730–734.
- 45. Bjordal, J.M., Couppe, C., and Ljunggren, A.E. (2001). Low level Laser Therapy for Tendinopathy: Evidence of a Dose Response Pattern. Phys. Ther. Rev. 6, 91–99.
- Robertson, V.J. (2003). Therapeutic Ultrasound: Re-evaluating the Evidence. Physiotherapy Singapore. 6, 28–35.
- Crawford, F., and Thomson, C. (2003). Interventions for Treating Plantar Heel Pain. Cochrane Database Syst. Rev. (3):CD000416.
- 48. Tuner, J., and Hode, L. (1998). It's All in the Parameters: A Critical Analysis of Some Well-Known Negative Studies on Low Level Laser Therapy. J. Clin. Laser Med. Surg. 16, 245–248.
- Chow, R.T., Heller, G.Z., and Barnsley, L. (2006). The Effect of 300mW, 830nm Laser on Chronic Neck Pain: A Double Blind Randomised, Placebo-Controlled Study. Pain. 124, 201–210.
- Farrar, J.T., Portenoy, R.K., Berlin, J.A., et al. (2000). Defining the Clinically Important Difference in Pain Outcome Measures. Pain. 88, 287–294.
- Farrar, J.T., Young, J.P., LA Moreaux, L., et al. (2001). Clinical Importance of Changes in Chronic Pain Intensity Measured on an 11 Point Numerical Pain Rating Scale. Pain. 94, 149–158.
- Todd, K.H., Funk, K.G., Funk, J.P., et al. (1996). Clinical Significance of Reported Changes in Pain Severity. Ann. Emerg. Med. 27, 485–489.
- Chow, R.T., Barnsley, L.B., Heller, G.Z., et al. (2004). A Pilot Study of Low-Power Laser Therapy in The Management of Neck pain. J. Musculoskelet. Pain. 12, 71–81.
- Emanual, E.J., and Miller, F.G. (2001). The Ethics of Placebo-Controlled Trials: a Middle Ground. N. Engl. J. Med. 345(12), 915–920.
- 56. Enserink, M. (2000). Helsinki's new clinical rules: fewer placebos, more disclosure. Science. 290, 418–419.
- Ejnisman, B., Andreoli, C.V., Soares, B.G.O., et al. (2004). Interventions for Tears of the Rotator Cuff in Adults. Cochrane Database Syst. Rev. (1):CD002758.

- Stasinopoulos, D.I., and Johnson, M.I. (2005). Effectiveness of Low-Level Laser Therapy for Lateral Elbow Tendinopathy. Photomed. Laser Surg. 23, 425–430.
- Maher, S. (2006). Is Low-Level Laser Therapy Effective in the Management of lateral Epicondylitis. Phys. Ther. 86, 1161– 1167.
- Bjordal, J.M. (2007). On "Is Low-level Laser Therapy Effective" Maher S. Phys Ther. 2006; 86:1161–1167. (Letter to the Editor). Phys. Ther. 87, 224–225.
- Bjordal, J.M., Lopes-Martins, R.A.B., Joensen, J., et al. (2008). A Systematic Review with Procedural Assessments and Meta-Analysis of Low-Level Laser Therapy in Lateral Elbow tendinopathy (Tennis Elbow). BMC Musculoskelet. Disord. 9, 75.
- 62. Bjordal, J.M., and Greve, G. (1998). What May Alter the Conclusions of Reviews? Phys. Ther. Rev. 3, 121–132.

Address correspondence to: Steve Tumilty Centre for Physiotherapy Research, School of Physiotherapy University of Otago PO Box 56 Dunedin 9054 New Zealand

E-mail: steve.tumilty@otago.ac.nz